FAQ/Help |
Calendar |
Search |
Today's Posts |
![]() |
#11 | |||
|
||||
Member
|
According to the VP of Drug Safety at Biogen the chance of getting PML on Tysabri are lower than initially suspected based on the clinical trials. Maybe someone posted this article already.
http://www.medscape.com/viewarticle/702373 The incidence of PML in patients taking natalizumab for 1 year or more is 2.4 per 10,000 patients, 1.4 per 10,000 in patients treated for 18 months or more, and 3 per 10,000 in patients treated for 2 years or more, with confidence intervals "that are overlapping," said Dr. Bozic. I'm not sure what "confidence intervals overlapping" means.
__________________
On Tysabri and love it. . |
|||
![]() |
Thread Tools | |
Display Modes | |
|
|
![]() |
||||
Thread | Forum | |||
LDN Information & Check-in 2 | Multiple Sclerosis | |||
Tysabri Information & Check In | Multiple Sclerosis | |||
LDN Information & Check In | Multiple Sclerosis | |||
Part 2...Medicare Part D/Prescription Coverage | Parkinson's Disease |